Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 155,403

Document Document Title
WO/2018/068336A1
The present invention provides antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.  
WO/2018/068691A1
Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.  
WO/2018/068357A1
Disclosed are a compound as shown in formula I, or a pharmaceutically acceptable salt, a crystal form, a solvate thereof, wherein Z is selected from (II), (III), (IV) or (V); R1 is selected from H or (VI); R2 is selected from (VII) or (V...  
WO/2018/068131A1
The present invention provides substituted hydroxystilbenes compounds of the general formula I that inhibit the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compounds can be ...  
WO/2018/068090A1
The present invention relates generally to the field of glycanics and its application to the generation of glycoconjugates for therapeutic use. The present invention also relates to process for the preparation of glycoconjugates.  
WO/2018/071343A1
Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventi...  
WO/2018/071681A1
The invention includes methods for preparing inactivated exosomes isolated from cancer stem cells, as well as inactivated exosomes produced by the inventive method. The invention also provides methods for inhibiting the growth and/or pro...  
WO/2018/071741A1
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoim...  
WO/2018/069536A1
The present invention provides TPCS2a, gemcitabine and optionally another cytotoxic agent, preferably cisplatin, for use in a method of treating a cholangiocarcinoma in a human patient comprising a photochemical internalization method. R...  
WO/2018/069468A1
The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors,and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic d...  
WO/2018/071323A1
A method for assessing susceptibility to nausea of a patient comprises assessing the GSH recycling dependent antioxidant activity of the patient's blood cells prior to receiving an emetogenic agent, e.g., a cytostatic agent or a surgical...  
WO/2018/070069A1
The present invention provides a medicine comprising: a Toll-like receptor agonist; and LAG-3 protein, a variant thereof, or a derivative thereof.  
WO/2018/069490A1
A compound of formula (I) : (I) and its conjugates.  
WO/2018/069471A1
The present invention provides novel uses and methods for T cell based immunotherapies. Specifically, the invention relates to novel ligands, targets and nucleic acids and vectors encoding said targets that are useful for modulating T ce...  
WO/2018/068769A1
Provided are the use of dihydroberberine type compounds and (±) -8-acetonyldihydroberberine type compounds in the preparation of products for preventing, alleviating and/or treating tumour diseases associated with the STAT3 signaling pa...  
WO/2018/068257A1
Provided is a universal CAR-T cell expressing specific CAR and not expressing TCR. Also provided is a preparation method for the universal CAR-T cell, the method comprising the following steps: 1) introducing sgRNA molecules and Cas9 mol...  
WO/2018/071307A1
A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2- hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino ]-1-methyl-2-oxo- ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treati...  
WO/2018/068739A1
The present invention relates to alkynyl heterocyclic compounds having inhibitory effects on the protein kinase activity, and to the preparation and use thereof. In particular, disclosed are alkynyl heterocyclic compounds as shown in for...  
WO/2018/068354A1
Provided are a siRNA of the human interleukin 6, a recombinant expression CAR-T vector, and a construction method and a use thereof. The siRNA can be used in the treatment of acute B-cell lymphocytic leukemia with CAR19-T for eliminating...  
WO/2018/068182A1
The present disclosure provides antibodies and antigen binding fragments against CTLA4, which can block the binding of CTLA4 to its ligand. The antibodies of disclosure provide agents for treating diseases, such as cancer.  
WO/2018/069892A1
This application relates to various crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy) -N-methylpicolinamide hydrochloride salts as well as compositions and methods of using the same. In some embodiments th...  
WO/2018/068652A1
An anti-EGFR and anti-CD3 bispecific antibody and applications thereof. The bispecific antibody can be specifically bound to tumor cell surface antigen epidermal growth factor receptors (EGFRs) and immune cell surface antigen cluster-of-...  
WO/2018/068756A1
Genetically modified non-human animals that express a human or chimeric (e.g., humanized) B-and T-Lymphocyte-Associated Protein (BTLA or CD272), and methods of use thereof are provided.  
WO/2018/071154A1
The present invention provides an invasive cancer stem cell (iCSC) or a substantively homogeneous cell population including said iCSC based on a cell-surface biomarker specifically localizing to the invadopodia of said iCSC. The present ...  
WO/2018/071447A1
Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors o...  
WO/2018/068282A1
Provided are compounds of formula (I),wherein R 1, Y, X 1, X 2, R 2, R 3, R 4, R 5, R 6 and m have any of the values defined in the specification and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment o...  
WO/2018/068758A1
Disclosed is the medical use of an anti-c Met antibody-cytotoxic drug conjugate. In particular, disclosed are an anti-c-Met antibody, an antigen-binding fragment of c-Met, a chimeric antibody and humanized antibody comprising the anti-c-...  
WO/2018/068666A1
Provided are a new microtubule protein inhibitor and applications therefor, said microtubule protein inhibitor being a series of compounds based on substituted heterocyclic skeletons, having as targets the colchicine binding sites of tub...  
WO/2018/069467A1
This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the ...  
WO/2018/070936A1
The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a V...  
WO/2018/069525A1
The present invention provides a novel class of dithiocarbamate-metal complexes and their uses in medicine. Also provided by the invention are combinations and pharmaceutical compositions, comprising a dithiocarbamate (or thiuram disulph...  
WO/2018/068695A1
The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes CTLA-4. Also provided are methods of making and using these constructs.  
WO/2018/069145A1
The present invention relates to the enhancement of the efficacy of anticancer agents by a composition comprising an aqueous phase, an oil phase, EPA and DHA for use in the treatment of solid tumors, wherein EPA and DHA are present in an...  
WO/2018/068757A1
New anticancer and anti-obesity agents based on the cyclic peptide compounds are disclosed, and its preparation and application method for treating cancer and obesity diseases are also disclosed.  
WO/2018/069924A1
The invention relates to a none cytotoxic combination therapy comprising at least one angiogenesis inhibitor, at least one non-steroidal anti-inflammatory agent, at least one NFk B inhibitor and at least one H2 blocker and a pharmaceutic...  
WO/2018/068201A1
The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes CTLA-4. Also provided are methods of making and using these constructs.  
WO/2018/068759A1
The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring brid...  
WO/2018/069289A1
The present invention is concerned with antibody-drug conjugates (ADCs) for use in cancer immunotherapy. The invention provides an ADC in combination with an immunotherapy (IMT) agent for use in cancer treatment. For example: The inventi...  
WO/2018/068766A1
Disclosed are an optimised chimeric antigen receptor, a gene and a recombinant expression vector thereof, an engineered CD19-targeted T cell, and an application thereof. The chimeric antigen receptor is made up of CD19ScFv, the hinge dom...  
WO/2018/071576A1
Methods are disclosed for treating a subject with a solid tumor. The methods can include administering to the subject a therapeutically effective amount of (1) a CD300f inhibitor, (2) dendritic cells comprising an inactivated gene encodi...  
WO/2018/069375A1
The present invention relates to linker-drug compounds (LDs) and antibody-drug conjugates (ADCs) comprising a non-linear self-immolative linker, which is cleavable or transformable under appropriate conditions and which reduces the hydro...  
WO/2018/071404A1
The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.  
WO/2018/068832A1
There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said co...  
WO/2018/068283A1
Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the...  
WO/2018/071767A1
Disclosed herein, are antibody-polymer-drug conjugates. The conjugate comprises a targeting moiety, one or more polymers, and one or more therapeutic agents. Also described herein, are compositions comprising the conjugates, methods of t...  
WO/2018/068135A1
The present description relates to methods for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell. The methods involve contacting the cell with the polypeptide cargo in the...  
WO/2018/070900A1
The aim of the present invention is to create novel MEK1, MEK2 and MEK1/2 inhibitors which have lower toxicity in long-term dosage. This aim is achieved by the novel compound N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimet h...  
WO/2018/071454A1
Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RE...  
WO/2018/068399A1
Provided is the use of a compound represented by formula I, a stereoisomer, or a pharmaceutically acceptable salt, or a solvate, or a crystalline form, or an isotopologue thereof in preparation of a sensitizer for a tumour immunotherapeu...  
WO/2018/068665A1
Provided are a new microtubule protein inhibitor and applications therefor, said microtubule protein inhibitor being a series of compounds based on substituted heterocyclic skeletons, having as targets the colchicine binding sites of tub...  

Matches 1 - 50 out of 155,403